Cell & Gene Therapy drug Delivery Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Cell & Gene Therapy Drug Delivery Devices Market is anticipated to expand from USD 1.56 billion in 2025 to USD 2.79 billion by 2031, reflecting a compound annual growth rate (CAGR) of 10.17%. This market comprises specialized technologies created to precisely and effectively administer genetic material and therapeutic cells to patients. Primary catalysts for this expansion include heavy investments in research and development, a rising number of regulatory clearances for advanced therapies, and a strong pipeline of innovative treatments moving through clinical phases. Highlighting this trend, the Alliance for Regenerative Medicine reported that the sector raised $11.1 billion across 216 financing rounds in 2025. Furthermore, accelerated regulatory momentum is evident, as the European Medicines Agency's Committee for Advanced Therapies granted marketing authorization for Vyjuvek in April 2025 and issued a positive draft opinion for Aucatzyl in May 2025.

Conversely, the market faces a notable obstacle in the form of high manufacturing costs and the complex nature of developing these highly specialized delivery systems and their corresponding therapeutic payloads. Nevertheless, the sector is steadily moving forward despite these barriers. As noted by the Alliance for Regenerative Medicine, the introduction of two new blockbuster cell and gene therapy products in 2025 highlights the strong commercial potential and the growing availability of these cutting-edge treatments for patients.

Market Driver

The rising number of regulatory authorizations for cell and gene therapies is a major catalyst for the global drug delivery devices market in this sector. As additional advanced treatments secure approval, the necessity for accurate and effective delivery mechanisms grows substantially. Such regulatory endorsements confirm the clinical value of these treatments, stimulating ongoing investment in the accompanying delivery technologies. For example, the FDA's authorization of Waskyra® (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome on December 9, 2025, and Zevaskyn (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa on April 29, 2025, underscores a rising embrace of gene-corrected solutions. These milestone approvals directly stimulate demand for specialized equipment designed to safely and efficiently deliver intricate biological payloads, ultimately expanding the patient population reliant on sophisticated delivery systems.

Additionally, technological breakthroughs in cell and gene delivery platforms act as a critical force propelling market growth. These innovations are centered on improving the safety, efficiency, and targeting precision of delivery techniques, all of which are essential for the effective implementation of these therapies. Key progress includes enhanced non-viral delivery mechanisms and innovative viral vector engineering.

Demonstrating this progress, an April 2026 article by the National Institutes of Health, titled "NIH-funded breakthrough shrinks CRISPR for precision delivery in the body," detailed a newly discovered, compact CRISPR gene-editing system using the Al3Cas12f enzyme, which fits seamlessly within adeno-associated virus vectors for precise targeting. Such leaps forward allow for the management of a broader spectrum of diseases and yield better patient results through highly accurate administration. Moreover, global research trends mirror this momentum; the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot revealed that the Asia-Pacific region overtook North America in clinical trial volume during 2025, highlighting a geographically expanding requirement for advanced delivery apparatuses.

Market Challenge

A primary hurdle restricting the global cell and gene therapy drug delivery devices market is the underlying complexity and steep production expenses linked to manufacturing specialized delivery systems alongside their therapeutic payloads. Frequently, these production workflows depend on older, resource-heavy technologies that are challenging to scale, driving up the cost of therapy and restricting patient availability to these modern treatments. The massive financial investment needed to expand sophisticated manufacturing operations for both the therapies and their complex delivery vehicles forms a formidable economic obstacle, limiting wider market adoption and the overall reach of these pioneering medical solutions.

This significant economic strain actively slows market growth by escalating treatment expenses for both patients and healthcare networks. Consequently, there is a clear demand for substantial funding to help alleviate these prohibitive costs. As an illustration, the Alliance for Regenerative Medicine's Q3 2025 Sector Snapshot reported that Kernal Bio received $48 million in funding to formulate more affordable CAR-T cell therapies, highlighting the immense capital being mobilized to tackle these fundamental financial barriers. Ultimately, the high production costs of these therapeutic elements result in steeper price tags for the combined therapy and delivery device, hindering the industry's capacity to reach broad commercialization and widespread patient access.

Market Trends

The Global cell and gene therapy drug delivery devices market is being heavily shaped by a shift toward patient-focused and home-based delivery mechanisms, which emphasize ease of use and broader treatment accessibility. This movement is accelerating the creation of delivery tools that are less intrusive, easier to handle, and capable of being used away from conventional medical facilities. These improvements are especially vital for treatments that demand ongoing or repeated dosing, as they significantly lessen the strain on both healthcare systems and the patients themselves. Highlighting this push for swift, customized care, a July 2025 update by the Innovative Genomics Institute on "CRISPR Clinical Trials: A 2025 Update" noted that the first personalized CRISPR therapy was successfully created and administered to a patient within a mere six-month timeframe.

Another prominent trend transforming the industry is the digitalization and automation of delivery processes, which drastically improve quality control, scalability, and production efficiency. Such advancements help counteract the high expenses and profound complexities tied to the creation of cell and gene therapies, which rely on highly specialized parts and complicated procedures.

By incorporating digital platforms and automated machinery into the production and delivery chains, companies can ensure batch uniformity, reduce human mistakes, and streamline overall operations. Exemplifying this progress, Lonza announced on December 11, 2025, in "Lonza's Cocoon® Platform Receives Advanced Manufacturing Technologies (AMT) Designation From The U.S. FDA," that its Cocoon® Platform earned this designation from the U.S. FDA, an acknowledgment of its enclosed, automated cell therapy manufacturing design that is expected to ease regulatory pathways and encourage wider technological utilization.

Key Market Players

• Becton Dickinson and Company
• Novartis AG
• Amgen Inc.
• Kite Pharma Inc.
• Pfizer Inc.
• Bausch & Lomb Incorporated
• Bluebird bio Inc.
• Castle Creek Biosciences Inc
• Dendreon Pharmaceuticals LLC
• Helixmith Co. Ltd

Report Scope

In this report, the Global Cell & Gene Therapy drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy drug Delivery Devices Market, By Type:

• Subretinal Injection Cannula
• Extension Tube
• Intravenous Catheter
• Sterile Insulin Syringe
• Prefilled Syringe
• Infusion Bags

Cell & Gene Therapy drug Delivery Devices Market, By Route of Administration:

• Oral
• Intravenous
• Ocular
• Transdermal
• Others

Cell & Gene Therapy drug Delivery Devices Market, By Method:

• In Vitro
• Ex Vivo

Cell & Gene Therapy drug Delivery Devices Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy drug Delivery Devices Market .

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.